|
Drug Interactions: (Gruenwald et al. 2000)
- MAOI - although there is poor documentation, concomitant administration of St. John's wort and a MAOI, such as tranylcypromine or phenelzine, may lead to increased effects and possible toxicity (hypertensive crisis).
- It is prudent to avoid concomitant use with beta-sympathomimetic amines, e.g., ma huang or pseudoephedrine.
- SSRIs - St. John's Wort taken concomitantly with an SSRI (selective serotonin reuptake inhibitor), such as fluoxetine, paroxetine, sertraline, fluvoxamine or citalopram, may lead to an increased effect and possible toxicity (e.g., "serotonin syndrome" - sweating, tremor, flushing, confusion and agitation). St. John's wort has slight serotonin reuptake properties. A case report suggests that coadministration of St. John's wort with paroxetine has resulted in a clinical syndrome resembling a sedative/hypnotic intoxication.
- Tannic acids present in St. John's wort may inhibit the absorption of iron.
- Concomitant use with other photosensitizers, such as tetracyclines, sulfonamides, thiazides, quinolones, piroxicam and others should be avoided.
- St. John's wort extract has been reported to significantly prolong narcotic-induced sleeping times and to antagonize the effects of reserpine.
- Cyclosporine - decreased serum concentrations have occurred with use of St. John's wort. Acute cellular transplant rejection in heart transplant patients due to an interaction between St. John's wort and cyclosporine has been reported. St. John's wort has been proven to induce the cytochrome P450 enzyme system, the major pathway for cyclosporine metabolism. Heart transplant rejection has been reported as soon as 3 weeks after St. John's wort is added to the drug regimen of heart transplant patients maintained on cyclosporine therapy.
- Indinavir - an open label study was conducted involving healthy volunteers that were administered 800 mg indinavir (a protease inhibitor used as a component of highly active antiretroviral therapy [HAART] to treat HIV infection and AIDS) every 8 hours along with 300 mg St. John's wort standardized to 0.3% hypericin 3 times daily. Results showed a 57% reduction in the area under the curve for the protease inhibitor and an 81% decrease of the extrapolated 8-hour indinavir trough value. The authors concluded that a reduction of this magnitude could lead to development of drug resistance and treatment failure.
- Clinicians are warned that St. John's wort may significantly affect plasma concentrations of any drug that is metabolized by the cytochrome P450 system.
- Ethinyloestradiol and desogestrel (combined oral contraceptive) - breakthrough bleeding has occurred with concomitant use of St. John's wort.
- Hypericin causes a reduction in barbiturate-induced sleeping times.
- Theophylline - St. John's wort has caused decreased theophylline levels on a patient stabilized on theophylline therapy.
- Co-administration of St. John's wort extract with digoxin resulted in a significant decrease in digoxin activity as compared to a placebo. Therefore, St. John's wort may reduce efficacy of digoxin and make a patient a nonresponder, whereas increased toxicity may be anticipated after withdrawal of the herb.
- St. John's Wort (600-900 mg/day) taken concomitantly with sertraline (50-75 mg/day) after 2 to 4 days, resulted in a presumed serotonin syndrome consisting of dizziness, nausea, vomiting, headache, epigastric pain, anxiety, confusion, and/or feelings of restlessness and irritability. Cyproheptadine was used to reverse the symptoms and after discontinuation of the herb-drug therapy, all symptoms resolved.
- Nefazadine (100 mg twice daily) and St. John's wort (300 mg three times daily) taken simutaneously resulted in nausea, vomiting and restlessness after 3 days of therapy. The symptoms improved after stopping the nefazadine and continuing with St. John's wort.
|